Listen
NOXAFIL 300 mg (posaconazole), triazole antifungal
INFECTIOUS DISEASE - New medicinal product
Opinions on drugs -
Posted on
Aug 23 2016
Reason for request
Inclusion
- NOXAFIL IV has Marketing Authorisation in the treatment of:
- healing of invasive aspergillosis, fusariosis, chromoblastomycosis/mycetomas and coccidioidomycosis, in patients refractory or intolerant to first-line antifungals.
- prophylaxis for invasive fungal infections in high-risk patients.
- No clinical benefit demonstrated when compared with oral forms of posaconazole.
- Its place in the therapeutic strategy is the same as that of the oral presentations currently available. The injectable form may have a benefit in patients who cannot receive oral forms.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
Contact Us
Évaluation des médicaments
